Technical Analysis for ELEV - Elevation Oncology, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Up | Down | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
20 DMA Support | Bullish | 0.00% | |
Pocket Pivot | Bullish Swing Setup | 0.00% | |
Bollinger Band Squeeze | Range Contraction | 0.00% | |
BB Squeeze + Upper Band Touch | Range Contraction | 0.00% | |
Upper Bollinger Band Touch | Strength | 0.00% | |
20 DMA Support | Bullish | 4.07% | |
Bollinger Band Squeeze | Range Contraction | 4.07% | |
20 DMA Support | Bullish | 0.79% | |
Bollinger Band Squeeze | Range Contraction | 0.79% | |
Outside Day | Range Expansion | 0.79% |
Alert | Time |
---|---|
Possible Pocket Pivot | 3 days ago |
Up 10% | 3 days ago |
Up 1 ATR | 3 days ago |
60 Minute Opening Range Breakout | 3 days ago |
Rose Above Upper Bollinger Band | 3 days ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/02/2024
Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically-defined patient populations in the United States. Its lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. The company was incorporated in 2019 and is based in New York, New York.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Cancer Clinical Medicine Life Sciences Immunology Health Sciences Pharmacy Treatment Of Cancer Monoclonal Antibody Advanced Solid Tumors Duligotuzumab
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Cancer Clinical Medicine Life Sciences Immunology Health Sciences Pharmacy Treatment Of Cancer Monoclonal Antibody Advanced Solid Tumors Duligotuzumab
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 5.8299 |
52 Week Low | 0.363 |
Average Volume | 762,205 |
200-Day Moving Average | 2.10 |
50-Day Moving Average | 4.18 |
20-Day Moving Average | 3.67 |
10-Day Moving Average | 3.69 |
Average True Range | 0.36 |
RSI (14) | 50.98 |
ADX | 11.12 |
+DI | 21.16 |
-DI | 18.75 |
Chandelier Exit (Long, 3 ATRs) | 3.39 |
Chandelier Exit (Short, 3 ATRs) | 4.27 |
Upper Bollinger Bands | 3.99 |
Lower Bollinger Band | 3.35 |
Percent B (%b) | 0.77 |
BandWidth | 17.29 |
MACD Line | -0.09 |
MACD Signal Line | -0.14 |
MACD Histogram | 0.0525 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 4.72 | ||||
Resistance 3 (R3) | 4.72 | 4.44 | 4.57 | ||
Resistance 2 (R2) | 4.44 | 4.21 | 4.43 | 4.52 | |
Resistance 1 (R1) | 4.14 | 4.08 | 4.29 | 4.13 | 4.47 |
Pivot Point | 3.85 | 3.85 | 3.93 | 3.85 | 3.85 |
Support 1 (S1) | 3.55 | 3.63 | 3.70 | 3.55 | 3.21 |
Support 2 (S2) | 3.27 | 3.49 | 3.26 | 3.16 | |
Support 3 (S3) | 2.97 | 3.27 | 3.11 | ||
Support 4 (S4) | 2.96 |